Inclusion Criteria:

1. Squamous cell carcinoma of the cervix (any grade) or histologically confirmed grade 1 or 2 adenocarcinoma of cervix
2. FIGO stage IA2 or IB1 disease
3. Tumor diameter </= 2 cm on physical exam & imaging studies (if performed)
4. No lymphovascular space invasion present on biopsy or previous cone
5. Cone margins & ECC specimen negative for invasive cancer, CIN 2, CIN3 or adenocarcinoma-in-situ (1 repeat cone/ECC permitted)
6. Patients eligible for study if Cone and ECC was performed prior to enrollment in study, provided the above pathologic eligibility criteria are met & cone/ECC was performed within 12 wks of enrollment
7. Patients must sign approved ICD
8. If patient is of childbearing potential, must have a negative blood or urine pregnancy test prior to surgery.
9. Patients who have had a simple hysterectomy (cut-through hysterectomy) prior to enrollment are eligible, provided the above pathology criteria are met. If lymphadenectomy was performed the lymph nodes must be negative. If lymphadenectomy was not performed, patients will undergo this procedure as part of the study.
10. Less than 10mm of cervical stromal invasion

Exclusion Criteria:

1. Clear cell, neuroendocrine, adenosquamous, serous carcinoma or other high-risk histologies
2. Grade 3 adenocarcinoma
3. FIGO stage IA1, IB2, II, III or IV disease
4. Tumors >2 cm in diameter on physical exam or imaging studies (if performed)
5. Presence of LVSI
6. Cone margins or ECC specimen positive for invasive cancer, CIN2, CIN3 or adenocarcinoma-in-situ (one repeat cone permitted)
7. Neoadjuvant radiation therapy or chemotherapy for cervical cancer
8. Patients unwilling or unable to provide informed consent for the study
9. Greater than or equal to 10mm of cervical stromal invasion